Why Is ResMed Stock Down Today?

Sonal Goyal

15 July 2026 10:17 PM AEST

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

ResMed (ASX:RMD) fell -3.04% today — one of the sharper single-session declines in the ASX healthcare sector — to close at $27.74, trading between $27.51 and $27.81. Today's move extends a difficult twelve months for the sleep apnea and respiratory device manufacturer, which has returned -28.41% over the period, amid ongoing market questions about the competitive impact of new obesity treatment drugs on sleep apnea device demand.

Company Overview

ResMed designs and manufactures medical devices for the treatment of sleep apnea and other respiratory conditions, including continuous positive airway pressure (CPAP) machines and related masks and accessories, serving patients and healthcare providers globally.

Business at a Glance

ResMed Inc trades on the ASX under the code RMD. It is broadly positioned as a sleep apnea and respiratory devices business. Interests commonly associated with the company include:

A designer and manufacturer of sleep apnea treatment devices, including CPAP machines
Products also span broader respiratory care and connected health software
A global customer base spanning patients, healthcare providers and durable medical equipment suppliers

Readers should note that corporate portfolios evolve over time through development, acquisitions and divestments, and the company's own disclosures remain the authoritative source for current details.

Strategic Positioning

ResMed's strategic position has historically rested on its market leadership in CPAP devices and masks for sleep apnea treatment, supported by ongoing investment in digital health platforms that help improve patient compliance and outcomes. The company has expanded beyond hardware into software and services aimed at supporting the broader sleep and respiratory care ecosystem.

Recent Market Context

ResMed's share price has faced pressure amid market speculation about whether new weight-loss and obesity treatment medications, which can reduce some forms of sleep apnea by supporting weight loss, might reduce long-term demand for CPAP devices. Today's decline and the broader annual pressure reflect this ongoing market debate, alongside the normal cyclical and competitive dynamics of the medical device sector.

Market participants often distinguish between short-term price swings and longer-term structural themes. A move in a share price on any given day may reflect trading flows, broader index moves or sector rotation rather than a change in the underlying business.

Why This Stock May Be Gaining Investor Attention

ResMed attracts investors interested in sleep apnea and respiratory device therapy as a category, with particular focus on the evolving relationship between new pharmaceutical weight-loss treatments and the sleep apnea patient population. Today's decline will draw further attention to how this dynamic is playing out in the company's patient volumes and device sales.

None of these observations constitutes a recommendation. They form part of the mosaic that market participants may assess when considering the stock.

Sector Dynamics and the Bigger Picture

The healthcare sector is shaped by forces well beyond any single company, including government funding and reimbursement policy, demographic trends, regulatory approval pathways and broader shifts in investor sentiment toward growth and defensive healthcare assets. This wider context frames the environment for names such as ResMed Inc.

For long-term observers, the interplay between these structural themes and shorter-term cycles is central. A favourable long-run narrative does not prevent periods of weakness along the way, and near-term softness does not necessarily undermine a longer-term case.

Key Catalysts Investors May Monitor

Market participants following the company may keep an eye on a range of developments. These are potential points of interest, not signals to act:

Patient diagnosis and device prescription volumes for sleep apnea treatment
The evolving relationship between obesity treatment medications and sleep apnea device demand
New product launches and technology improvements in CPAP devices and masks
Digital health platform adoption and its effect on patient compliance and retention
Competitive dynamics from other respiratory device manufacturers
Regulatory and reimbursement developments in key healthcare markets

These checkpoints are best treated as a framework for staying informed, not a checklist for action.

Key Risks and Uncertainties

As with any healthcare company, a range of risks and uncertainties apply. These include, but are not limited to:

Ongoing market uncertainty about the long-term effect of obesity treatment drugs on sleep apnea device demand
Competitive pressure from other CPAP and respiratory device manufacturers
Regulatory and reimbursement policy changes in key healthcare markets
Currency exposure given significant international revenue
A challenging annual return reflects sustained market concerns that require further clarity to resolve

This list is not exhaustive, and the relative importance of each risk can change over time. Companies typically outline the risks relevant to their circumstances in their own disclosures, which readers are encouraged to consult.

Balanced Outlook

Any balanced view of ResMed Inc weighs the possibilities against the risks. Conditions may offer tailwinds at times, but outcomes will depend on how the company performs and on circumstances outside its control.

Rather than reaching for firm predictions, market participants may prefer to monitor the milestones and metrics discussed above, updating their views as new information emerges. Ultimately, what any of this means for a given person depends on their own situation, and seeking advice from a licensed financial professional can help put it in context.

Considerations That May Support Interest

Established market leadership position in CPAP devices and masks
A significant installed patient base providing recurring mask and accessory revenue
Digital health platform investments that may support improved patient outcomes and retention over time

Considerations That Warrant Caution

The obesity drug and sleep apnea device demand question remains an unresolved market debate that requires ongoing monitoring
Today's sharp decline suggests continuing sensitivity to this broader narrative
Competitive dynamics in respiratory device markets continue to evolve

Weighing these considerations against one another is a matter for each reader, informed by their own research and, where appropriate, professional guidance.

FAQs

Q: What does ResMed make?

A: ResMed manufactures medical devices for treating sleep apnea and other respiratory conditions, including CPAP machines, masks and related digital health platforms.

Q: Why did ResMed fall today?

A: RMD fell -3.04% to $27.74 today. This may reflect ongoing market concerns about the effect of obesity treatment medications on sleep apnea device demand, or broader healthcare sector sentiment.

Q: How do obesity drugs affect ResMed's business?

A: Some obesity treatment medications can help patients lose weight, which may reduce sleep apnea severity for some patients, creating market uncertainty about long-term demand for CPAP devices. The full extent of this effect remains an area of ongoing assessment.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.